Combining anti‑ulcer medicines with levofloxacin and amoxicillin to clear H. pylori infection

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a three‑arm, open‑label, randomized trial that assigns adults with urea breath test–confirmed H. pylori infection to one of three treatment arms. Each arm receives levofloxacin 500 mg plus amoxicillin 1 g together with either dexlansoprazole 60 mg, lansoprazole 30 mg, or vonoprazan 20 mg for 14 days. Participants are followed for eradication outcomes after treatment to compare H. pylori clearance rates between the regimens. The trial targets a local patient population with high baseline antibiotic resistance and aims to identify which acid suppression backbone yields the highest eradication when paired with levofloxacin-based therapy.

Why it matters

Who can join: the full rules

Inclusion Criteria:

Adult patients of both sexes, presenting to the out-patient departments of the participating healthcare centres, and diagnosed through a UBT to have H.Pylori infection by their physician will be eligible for enrolment in the study, but are currently not receiving any treatment for H.Pylori infection.

Exclusion Criteria:

1. Those who will not provide written consent for the study.
2. Patients with severe mental disability,
3. pregnant or lactating women,
4. those who are already on treatment for H.Pylori infection, and
5. those who have received any antibiotic within the last two weeks of enrolling in this study will be excluded.
6. Patients with known previous documented drug allergies for the current regime will be excluded from the trial

Where it's running

• Sindh Institute of Advanced Endoscopy and Gastroenterology (SIAG), DUHS
  Karachi, Pakistan Recruiting

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Comparing tegoprazan and PPIs for treating H. pylori infection

  This study is testing if tegoprazan, a new type of acid blocker, works better than traditional medications for treating H. pylori infections in patients who can have a gastroscopy.

  Recruiting Soonchunhyang University Hospital · Seoul · NCT06682533

• Eradicating H. Pylori with Argon Plasma During Endoscopy

  This study is testing a new argon plasma treatment during endoscopy to see if it can safely get rid of H. pylori infections in patients who haven't been treated yet.

  Recruiting Brigham and Women's Hospital · Boston, Massachusetts · NCT06529159

• Breath testing for gastric cancer screening

  This study is testing if breath tests can help find gastric cancer and related conditions in people who have cancer, precancerous lesions, or are at average risk.

  Recruiting at 3 sites University of Latvia · São Paulo and 4 other locations · NCT04022109

• Fecal transplant to help eradicate stubborn Helicobacter pylori infection

  This study tests whether giving a fecal microbiota transplant can help people with Helicobacter pylori infection that has not responded to standard treatments.

  Recruiting Phase 4 Sichuan Provincial People's Hospital · Chengdu, Sichuan · NCT07704255

• Fecal-guided simplified vonoprazan plus clarithromycin first-line therapy for H. pylori

  We are testing whether a two-drug regimen of vonoprazan plus clarithromycin clears H. pylori in adults whose fecal PCR shows no clarithromycin resistance mutations.

  Recruiting Peking University First Hospital · Beijing, Beijing Municipality · NCT07439445

• Bismuth-amoxicillin-vonoprazan triple therapy versus bismuth-based quadruple therapy for H. pylori infection

  This will test whether a 14-day bismuth-amoxicillin-vonoprazan triple therapy works better and is as safe as a 14-day bismuth-based quadruple therapy for adults with H. pylori infection.

  Recruiting Kaohsiung Medical University · Kaohsiung City · NCT07358130

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.